Bio-Thera Reports First Patient Dosing in P-I Study of BAT2606, a Proposed Biosimilar of Nucala (mepolizumab) for Severe Asthma

Published: Oct 14, 2022| Tags: Bio-Thera Solutions, BAT2606, Nucala, mepolizumab, Severe Asthma, Clinical Trial, P-I Study

Enliven Therapeutics Entered into a Definitive Merger Agreement with Imara for ~$594.1M

Published: Oct 14, 2022| Tags: Enliven Therapeutics, Merger Agreement, Imara, ELVN-002, ELVN-001, lung cancer, ~$574M, M&A

BridgeBio Pharma Presents P-I/II (CANaspire) Trial Results of BBP-812 for the Treatment of Canavan Disease at CNS 2022

Published: Oct 14, 2022| Tags: BridgeBio Pharma, BBP-812, Canavan Disease, Clinical Trial, P-I/II CANaspire Trial

GSK Reports P-III (AReSVi-006) Study Results of RSVPreF3 OA for the Treatment of Respiratory Syncytial Virus

Published: Oct 14, 2022| Tags: GSK, RSVPreF3 OA, Respiratory Syncytial Virus, Clinical Trial, P-III AReSVi-006 Study

AdAlta Collaborated with GPCR Therapeutics for Novel Therapies to Treat Cancer

Published: Oct 14, 2022| Tags: AdAlta, GPCR Therapeutics, Novel Therapies, Cancer, CXCR4-B2AR, AD-214, Pharma

Edgewise Therapeutics Reports 6-Month Interim (ARCH) Study Results of EDG-5506 for Becker Muscular Dystrophy

Published: Oct 14, 2022| Tags: Edgewise Therapeutics, EDG-5506, Becker Muscular Dystrophy, Clinical Trial, ARCH Study

Regeneron Reports the US FDA’s Acceptance of sBLA for Priority Review of Eylea to Treat Retinopathy of Prematurity

Published: Oct 13, 2022| Tags: Regeneron, Eylea, aflibercept, Retinopathy, Prematurity, Regulatory, US, FDA, sBLA, Priority Review

NanoString Collaborated with Visiopharm to Co-develop Integrated Workflows for Spatial Biology Solutions

Published: Oct 13, 2022| Tags: NanoString, Visiopharm, Integrated Workflows, GeoMx, AtoMx, Spatial Biology Solutions, Pharma

Pasithea Therapeutics Acquires AlloMek Therapeutics and Expands CNS-Focused Drug Development Pipeline

Published: Oct 13, 2022| Tags: Pasithea Therapeutics, AlloMek Therapeutics, CIP-137401, neurofibromatosis type 1, Noonan syndrome, Acquires, M&A

Astellas to Present P-III (SKYLIGHT 4) Study of Fezolinetant for Vasomotor Symptoms Associated with Menopause at NAMS 2022

Published: Oct 13, 2022| Tags: Astellas, Fezolinetant, Vasomotor Symptoms, Menopause, P-III, SKYLIGHT 4 Study, NAMS, 2022

Tavros Therapeutics Entered into a Five-Year Collaboration Agreement with Vividion Therapeutics to Discover and Enhance Targeted Oncology Programs

Published: Oct 13, 2022| Tags: Tavros Therapeutics, Vividion Therapeutics, Oncology Programs, Pharma

Pfizer and BioNTech Receive the US FDA’s Emergency Use Authorization for 10-µg Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booste

Published: Oct 13, 2022| Tags: Pfizer, BioNTech, Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine, 10-µg, Booster, US, FDA, Emergency Use Authorization

BeiGene Reports P-III (ALPINE) Trial Results of Brukinsa (zanubrutinib) for the Treatment of Chronic Lymphocytic Leukemia

Published: Oct 12, 2022| Tags: BeiGene, Brukinsa, zanubrutinib, Chronic Lymphocytic Leukemia, Clinical Trial, P-III ALPINE Trial

BridgeBio Pharma Reports First Patient Dosing in P-I/II Trial for BBP-398 + Lumakras (sotorasib) to Treat Non-Small Cell Lung Cancer

Published: Oct 12, 2022| Tags: BridgeBio Pharma, BBP-398, Lumakras, sotorasib, Non-Small Cell Lung Cancer, Clinical Trial, P-I/II Trial

Gilead Reports the US FDA's Acceptance of Trodelvy's sBLA for Priority Review to Treat Pre-Treated HR+/HER2- Metastatic Breast Cancer

Published: Oct 12, 2022| Tags: Gilead, Trodelvy, HR+/HER2- Metastatic Breast Cancer, regulatory, sBLA, Priority Review, US, FDA

Genentech Presents Two Year P-II (JEWELFISH) Study Results of Evrysdi (risdiplam) for the Treatment of Spinal Muscular Atrophy at WMS 2022

Published: Oct 12, 2022| Tags: Genentech, Evrysdi, risdiplam, Spinal Muscular Atrophy, WMS, 2022, Clinical Trial, JEWELFISH Study

AstraZeneca Entered into a Research Collaboration with Illumina to Accelerate AI-based Drug Target Discovery

Published: Oct 12, 2022| Tags: AstraZeneca, Illumina, AI-based Drug Target Discovery, PrimateAI, SpliceAI

Eli Lilly Entered into a Research Collaboration and License Agreement with Nimbus Therapeutics for Small Molecule Activators of AMPK

Published: Oct 12, 2022| Tags: Eli Lilly, Nimbus Therapeutics, Small Molecule Activators, AMPK, metabolic disorders

HanAll's Licensed Partner Entered into an Exclusive Sublicense Agreement with CSPC NBP Pharma for Batoclimab

Published: Oct 11, 2022| Tags: HanAll, CSPC, NBP Pharma, Batoclimab, HL161BKN, HL036, tanfanercept, dry eye disease

Regeneron Presents P-III Trial Results of Dupixent (dupilumab) for Eosinophilic Esophagitis in Children Aged 1 to 11 Years at UEG 2022

Published: Oct 11, 2022| Tags: Regeneron, Dupixent, dupilumab, Eosinophilic Esophagitis, P-III Trial, UEG, 2022

JW Therapeutics Receives the NMPA’s Approval for Carteyva (relmacabtagene autoleucel) sNDA to Treat Relapsed or Refractory Follicular Lymphoma

Published: Oct 11, 2022| Tags: JW Therapeutics, Carteyva, relmacabtagene autoleucel, sNDA, Follicular Lymphoma, NMPA Approval, Regulatory

Brainomix Collaborated with UK Government-Funded NCIMI for AI-Powered Technology in Lung Cancer

Published: Oct 11, 2022| Tags: Brainomix, NCIMI, AI-Powered Technology, e-ACT, Lung Cancer, MedTech

Merck Reports P-III (STELLAR) Trial Results of Sotatercept for the Treatment of Pulmonary Arterial Hypertension

Published: Oct 11, 2022| Tags: Merck, Sotatercept, Pulmonary Arterial Hypertension, Clinical Trial, P-III STELLAR Trial

Janssen Presents P-III (UNIFI) Study Results of Stelara (ustekinumab) for Active Ulcerative Colitis at UEG 2022

Published: Oct 11, 2022| Tags: Janssen, Stelara, ustekinumab, Active Ulcerative Colitis, P-III UNIFI Study, UEG, 2022

Janssen Presents P-IIa (VEGA) PoC Study Results of Guselkumab + Golimumab for Active Ulcerative Colitis at UEG 2022

Published: Oct 10, 2022| Tags: Janssen, Guselkumab, Golimumab, Active Ulcerative Colitis, P-IIa (VEGA) PoC Study, Clinical Trials, UEG, 2022

BIOCORP Signs an Agreement with Merck KGaA to Co-develop New Bluetooth-Enabled Drug Delivery Device

Published: Oct 10, 2022| Tags: BIOCORP, Merck KGaA, New Bluetooth-Enabled Drug Delivery Device, Mallya devices, Sanofi, Novo Nordisk, DigiHealth

Ascletis Reports Patients Dosing in Multiple-Dose Escalation P-I Clinical Trial of ASC10 for COVID-19

Published: Oct 10, 2022| Tags: Ascletis, Multiple-Dose Escalation, P-I Clinical Trial, ASC10, COVID-19

Pfizer and BioNTech’s Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster Receives Health Canada Authorization in Individuals Aged ≥12 Years

Published: Oct 10, 2022| Tags: Pfizer, BioNTech, Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine, Health Canada, Authorization, Regulatory

Innovent’s Cyramza (ramucirumab) Receives NMPA’s Approval for the Treatment of Hepatocellular Carcinoma

Published: Oct 10, 2022| Tags: Innovent, Cyramza, ramucirumab, Hepatocellular Carcinoma, Regulatory, NMPA Approval

Sciwind Biosciences Initiates the First Patient Dosing of XW014 in P-I for the Treatment of Obesity and Type 2 Diabetes

Published: Oct 10, 2022| Tags: Sciwind Biosciences, XW014, Obesity, Type 2 Diabetes, Clinical Trial, US

Related Post: PharmaShots Weekly Snapshots (October 03 - 07, 2022)